Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr John Anderson.

Newcastle AuthorsTitleYearFull text
Dr Karen Barker
Philip Berry
Professor Gareth Veal
Dr John Anderson
In vivo Modelling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis2019
Professor Colin Rees
Dr John Anderson
Professor Matt Rutter
Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative2017
Dr Christine Challen
Dr John Anderson
Professor Zofia Chrzanowska-Lightowlers
Professor Robert Lightowlers
Professor John Lunec
et al.
Recombinant human MDM2 oncoprotein shows sequence composition selectivity for binding to both RNA and DNA2012
Dr Rachel Crossland
Professor Stephen Proctor
Dr Brian Angus
Dr Stephen Crosier
Dr John Anderson
et al.
A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines2010
Dr Rachel Crossland
Dr John Anderson
Dr Brian Angus
Professor Stephen Proctor
Dr Stephen Crosier
et al.
A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines2010
Dr Rachel Crossland
Dr John Anderson
Dr Brian Angus
Professor Stephen Proctor
Dr Stephen Crosier
et al.
A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines2010
Dr John Anderson
Lynne Overman
Dr Katrina Wood
Professor Stephen Proctor
Dr Stephen Crosier
et al.
Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics2009
Dr Tryfonia Mainou-Fowler
Lynne Overman
Dr Katrina Wood
Dr Brian Angus
Professor Stephen Proctor
et al.
A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-22008
Dr Tryfonia Mainou-Fowler
Professor Stephen Proctor
Dr John Anderson
CD31 density is a new risk factor for patients with B-cell chronic lymphocytic leukaemia2008
Dr Tryfonia Mainou-Fowler
Dr John Anderson
Professor Stephen Proctor
CD31 density is a novel risk factor for patients with B-cell chronic lymphocytic leukaemia2008
Seamus Kelly
Dr John Anderson
Dr Brian Angus
Dr Christine Challen
Professor John Lunec
et al.
The predictive value of p53 and p33ING1b in patients with Dukes'C colorectal cancer2008
Dr Xiaomei Lu
Dr Simon Baudouin
Professor James Gillespie
Dr John Anderson
Professor Anne Dickinson
et al.
A comparison of CFU-GM, BFU-E and endothelial progenitor cells using ex vivo expansion of selected cord blood CD133+ and CD34+ cells2007
Dr Xiaomei Lu
Dr Simon Baudouin
Professor James Gillespie
Dr John Anderson
Professor Anne Dickinson
et al.
A comparison of CFU-GM, BFU-E and endothelial progenitor cells using ex vivo expansion of selected cord blood CD133+ and CD34+ cells2007
Dr Tryfonia Mainou-Fowler
Lynne Overman
Dr Katrina Wood
Dr Stephen Crosier
Dr Brian Angus
et al.
A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-22007
Dr Rachel Crossland
Dr Christine Challen
Dr Bridget Wilkins
Dr Stephen Crosier
Dr John Anderson
et al.
Definitive identification of the Val617Phe mutation in myeloproliferative disorders using Real Time PCR utilising Roche Lightcycler/hybriprobe technology2007
Dr John Anderson
Professor Robert Lightowlers
Professor John Lunec
DNA and RNA Binding of a Bacterially Expressed Human MDM2 Onco-protein2007
Dr John Anderson
Dr Christine Challen
Dr Stephen Crosier
Professor John Lunec
MDM2 RNA binding is blocked by novel monoclonal antibody h-MDM2-F4-142007
Dr John Anderson
Dr Stephen Crosier
Lynne Overman
Dr Tryfonia Mainou-Fowler
Dr Sarah Fordham
et al.
Survivin in diffuse large B cell lymphoma: Evaluation as a prognostic marker2005
Dr John Anderson
Dr Stephen Crosier
Dr Jyotsna Shrimankar
Professor John Lunec
Dr Brian Angus
et al.
Downregulation of nuclear expression of the p33ING1b inhibitor of growth protein in invasive carcinoma of the breast2003
Dr Stephen Crosier
Dr Katrina Wood
Dr Philip Taylor
Professor Stephen Proctor
Dr Brian Angus
et al.
IAP survivin in diffuse large B cell lymphoma: Evaluation as a prognostic marker2003
Professor David Neal
Philip Powell
Monica Smith
Dr John Anderson
Barbara Hattrick
et al.
Prostate testing for cancer and treatment (ProtecT) feasibility study2003
Dr John Anderson
Professor John Lunec
Dr Brian Angus
The role of the tumour suppressor p33ING1b in human neoplasia2003
Andrew Lodge
Dr John Anderson
Dr Beate Haugk
Dr Brian Angus
Type 1 growth factor receptor expression in node positive breast cancer: Adverse prognostic significance of c-erbB-42003
Dr Brian Angus
Professor John Lunec
Dr Stephen Crosier
Andrew Lodge
Dr John Anderson
et al.
Comparative assessment expression of the inhibitor of growth 1 gene (ING1) in normal and neoplastic tissues2002
Dr John Anderson
GN1 anti-p33ING1b tumor suppressor2002
Dr John Anderson
GN2 anti-p33ING1b tumor suppressor2002
Dr John Anderson
Dr Katrina Wood
Professor John Lunec
Dr Andrew Hall
Dr Michael Reid
et al.
Loss of nuclear expression of the p33ING1b inhibitor of growth protein in childhood acute lymphoblastic leukaemia2002
Dr John Anderson
Dr Marie Mathers
Dr Niamh Leonard
Dr Stephen Crosier
Professor John Lunec
et al.
Nuclear to cytoplasmic compartment shift of the p33ING1b tumour suppressor protein is associated with malignancy in melanocytic lesions2002
Seamus Kelly
Dr John Anderson
Dr Brian Angus
Professor John Lunec
p33/ING1 nuclear expression and TP53 gene mutation in colorectal cancer and their association with clinical outcome2002
Dr John Anderson
Dr Stephen Crosier
Dr Jyotsna Shrimankar
Professor John Lunec
Dr Brian Angus
et al.
p33ING1b tumour suppressor immunohistochemical expression in invasive breast carcinomas2002
Seamus Kelly
Dr John Anderson
Dr Brian Angus
Professor John Lunec
TP53 and p33(Ing1) are co-determinants of prognosis in colorectal cancer2002
Dr Stephen Crosier
Dr Brian Angus
Dr John Anderson
Use of transgenomic wave and denaturing gel electrophoresis increases the sensitivity of FR3A-FR4 PCR detection of B-cell clonality2002
Professor John Lunec
Seamus Kelly
Dr John Anderson
Dr Brian Angus
Expression of p33/ING1 gene products in colorectal cancer and its correlation with survival2001
Dr John Anderson
Professor John Lunec
Dr Andrew Hall
Dr Michael Reid
Dr Brian Angus
et al.
p33(ING1b) tumour suppresser protein expression in childhood acute lymphoblastic leukaemia by immunohistochemistry2001
Dr Stephen Crosier
Dr John Anderson
Dr Marie Mathers
Dr Niamh Leonard
Dr Stephen Crosier
et al.
p33(ING1b) tumour suppresser protein expression in melanocytic lesions, an immunohistochemical study of 67 cases2001
Seamus Kelly
Professor John Lunec
Dr John Anderson
Dr Brian Angus
p33/ING1 nuclear expression in colorectal cancer and its correlation with metastasis and survival2001
Dr John Anderson
Dr Stephen Crosier
Professor John Lunec
Dr Brian Angus
p33ING1b tumour suppresser protein expression in thyroid lesions determined by immunohistochemistry2001
Dr Dina Tiniakos
Dr John Anderson
c-fos oncogene expression in human breast carcinoma2000
Andrew Lodge
Dr John Anderson
Dr Beate Haugk
Dr Brian Angus
Expression of topoisomerase III alpha in normal and neoplastic tissues determined by immunohistochemistry using a novel monoclonal antibody2000
Andrew Lodge
Dr John Anderson
Dr Beate Haugk
Dr Brian Angus
Expression of topoisomerase IIIα in normal and neoplastic tissues determined by immunohistochemistry using a novel monoclonal antibody2000
Dr Brian Angus
Professor John Lunec
Dr John Anderson
Monoclonal antibodies raised to products of the ING1 tumour suppressor gene locus.2000
Andrew Lodge
Dr John Anderson
Dr Brian Angus
Pixel-based image cytometry for quantification of nuclear antigen expression using Adobe Photoshop2000
Dr Dina Tiniakos
Dr John Anderson
Production and characterization of monoclonal antibodies to the human c-fos oncoprotein effective an routinely-processed tissues2000
Dr John Anderson
Dr Brian Angus
Professor John Lunec
Sequencing of ING1 tumour suppressor gene cDNAs generated from mRNA recovered from normal and neoplastic cell lines.2000
Andrew Lodge
Dr John Anderson
Dr Beate Haugk
Dr Brian Angus
Type 1 growth factor receptor and topoisomerase expression in breast cancer: Adverse prognostic significance of c-erbB-42000
Dr Craig Dixon
Dr Simon Sinclair
Dr Fraser Charlton
Dr John Anderson
Professor Peter Farr
et al.
Diagnosis of mycosis fungoides using histological evaluation, immunophenotyping and molecular analysis in formalin-fixed, parafin-embedded tissue1999
Andrew Lodge
Dr Andrew Hall
Dr Katrina Wood
Dr John Anderson
Dr Brian Angus
et al.
NCL-CD10-270: A new monoclonal antibody recognizing CD10 in paraffin- embedded tissue1999
Andrew Lodge
Dr Andrew Hall
Dr John Anderson
Dr Michael Reid
Dr Brian Angus
et al.

A study of the prognostic significance of topoisomerase IIα in childhood acute lymphoblastic Leukaemia

1998
Dr Katrina Wood
Dr Keith Mitchell
Professor Stephen Proctor
Dr Fergus Jack
Helen Bell
et al.
Development of new monoclonal antibodies recognising CD5, CD10, CD23, cyclin D1 and Ki67 in paraffin sections, and determination of their value in diagnosis of small B cell lymphoma1998
Dr John Anderson
Dr William Cowan
William Cunliffe
Dr Brian Angus
ER-CARD: a more sensitive method for detection of oestrogen receptor by immunohistochemistry1998
Dr John Anderson
Professor Thomas Lennard
Dr Brian Angus
A novel quantitative immunoassay system for p53 using antibodies selected for optimum designation of p53 status1997
Dr Mark Egan
Dr John Anderson
Dr William Cowan
Dr Brian Angus
Optimised determination of vascular invasion in breast cancer by immunohistochemistry for CD31: production of a novel monoclonal antibody and comparison with conventional assessment.1997
Professor Alan Calvert
Dr John Anderson
Professor David Neal
Professor John Lunec
Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer1996
Dr John Anderson
Dr Brian Angus
Determination of the clinical significance of cyclin a expression in human breast cancer using a novel monoclonal antibody1996
Dr John Anderson
Dr Brian Angus
Professor Thomas Lennard
p53 protein as a prognostic indicator in breast carcinoma: A comparison of four antibodies for immunohistochemistry1996
Dr John Anderson
Professor Thomas Lennard
Dr Brian Angus
Retinoblastoma protein in human breast carcinoma: Immunohistochemical study using a new monoclonal antibody effective on routinely processed tissues1996
Dr John Anderson
Dr Brian Angus
Professor Thomas Lennard

Determination of the prognostic value of cyclin D1 overexpression in breast cancer

1995
Dr Dina Tiniakos
Dr John Anderson
Dr Mary Robinson
Professor David Neal
c-jun oncogene expression in transitional cell carcinoma of the urinary bladder1994
Dr John Anderson
Dr Christopher Wright
Dr Brian Angus
NDP-K/nm23 expression in human breast cancer in relation to relapse, survival, and other prognostic factors: an immunohistochemical study1994
Dr John Anderson
Professor Geoff Toms
Dr Ronald Scott
Recognition of respiratory syncytial (RS) virus proteins by human and BALB/C CD4+ lymphocytes1991
Dr John Anderson
Jean Norden
Dr David Saunders
Professor Geoff Toms
Dr Ronald Scott
et al.
Analysis of the local and systemic immune responses induced in BALB/c mice by experimental respiratory syncytial virus infection1990
Dr John Anderson
Professor Geoff Toms
Dr Ronald Scott
Natural killer cell response to respiratory syncytial virus in the Balb/c mouse model1989
Dr Edward Routledge
Dr Tony Samson
Dr Ronald Scott
Dr John Anderson
Professor Geoff Toms
et al.
The purification of four respiratory syncytial virus proteins and their evaluation as protective agents against experimental infection in BALB/c mice1988